SFA Therapeutics
Develops orally administered, deuterated short-chain fatty acid small molecules intended to modulate the gut-immune axis and reset autoreactive immunity. Lead asset advanced through an open-label Phase 1b study in plaque psoriasis with a randomized, double-blind, placebo-controlled Phase 2 planned. The company operates a platform that creates deuterated new chemical entities from naturally occurring short-chain fatty acids and pursues patent protection for those candidates.
Industries
Nr. of Employees
small (1-50)
SFA Therapeutics
Jenkintown, Pennsylvania, United States
Products
SFA-002
Oral, once-daily deuterated short-chain fatty acid candidate for treatment of plaque psoriasis (mild-to-severe).
SFA-009
Oral deuterated short-chain fatty acid candidate under development for combination therapy in pancreatic cancer (preclinical stage indicated on site).
SFA-001
Oral deuterated short-chain fatty acid candidate indicated for liver cancer progression contexts (preclinical stage indicated on site).
SFA002
A microbiome-derived drug under clinical evaluation for the treatment of mild-to-moderate plaque psoriasis, currently in a Phase 1b clinical trial.
SFA001
A novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC) granted FDA Orphan Drug Designation (ODD).
small molecule drug candidates
Six small molecule drug candidates identified from SFA Therapeutics' platform targeting chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease, and IBS.
SFA-002
Oral, once-daily deuterated short-chain fatty acid candidate for treatment of plaque psoriasis (mild-to-severe).
SFA-009
Oral deuterated short-chain fatty acid candidate under development for combination therapy in pancreatic cancer (preclinical stage indicated on site).
SFA-001
Oral deuterated short-chain fatty acid candidate indicated for liver cancer progression contexts (preclinical stage indicated on site).
SFA002
A microbiome-derived drug under clinical evaluation for the treatment of mild-to-moderate plaque psoriasis, currently in a Phase 1b clinical trial.
SFA001
A novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC) granted FDA Orphan Drug Designation (ODD).
small molecule drug candidates
Six small molecule drug candidates identified from SFA Therapeutics' platform targeting chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease, and IBS.
Expertise Areas
- Clinical trial management
- Immunology and immunomodulation
- Small-molecule drug discovery
- Oral formulation development
Key Technologies
- Deuteration chemistry for small molecules
- Short-chain fatty acid-derived therapeutics
- Oral tablet formulation
- Gut-immune axis modulation
News & Updates
Open-label Phase 1b safety and efficacy study (n=28) in mild-to-severe plaque psoriasis reported statistically significant response rates across primary endpoints and no treatment-emergent adverse events in the cohort; Phase 2 planned.
Open-label Phase 1b safety and efficacy study (n=28) in mild-to-severe plaque psoriasis reported statistically significant response rates across primary endpoints and no treatment-emergent adverse events in the cohort; Phase 2 planned.